{"id":251404,"date":"2021-10-21T00:00:00","date_gmt":"2021-10-21T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidon0151-biopharma-pd-l1-epidemiology-mature-markets\/"},"modified":"2026-04-30T11:21:56","modified_gmt":"2026-04-30T11:21:56","slug":"epidon0151-biopharma-pd-l1-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidon0151-biopharma-pd-l1-epidemiology-mature-markets\/","title":{"rendered":"PD-L1 &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology has created a robust repository of the prevalence of biomarker- and mutation-defined treatment-eligible cancer populations. Using Clarivate\u2019s Biomarker Epidemiology, you can now save months of time and resources researching individual tumors in which a biomarker may be significant by quickly accessing data on the size of biomarker patient populations, based on diverse eligibility criteria and treatment settings.<\/p>\n<p>In addition to an extensive literature review and modeling, we leverage our in-house estimates of cancer incidence for solid and hematological malignancies. All estimates are rigorously researched and transparently reported.<\/p>\n<p><strong><abbr data-abbreviation-entity=\"5536\" title=\"programmed death-ligand 1\">PD-L1<\/abbr> epidemiology enables you to:<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Complete <abbr data-abbreviation-entity=\"5536\" title=\"programmed death-ligand 1\">PD-L1<\/abbr>-driven market-sizing assessments based on the size of patient populations and patient flows.<\/li>\n<li>Build the foundation of a market forecast for strategic planning for <abbr data-abbreviation-entity=\"5536\" title=\"programmed death-ligand 1\">PD-L1<\/abbr>-targeting for new and existing assets.<\/li>\n<li>Understand how the patient populations for <abbr data-abbreviation-entity=\"5536\" title=\"programmed death-ligand 1\">PD-L1<\/abbr> will evolve over time.<\/li>\n<li>Answer any question you may have about specific subpopulations, <abbr data-abbreviation-entity=\"5536\" title=\"programmed death-ligand 1\">PD-L1<\/abbr>, and the impact of new studies.<\/li>\n<\/ul>\n<p>Additional Capabilities:<\/p>\n<ul class=\"round-bullets\">\n<li>Patient-flow diagrams.<\/li>\n<li>Customizable populations and data visualization dashboards.<\/li>\n<li>Testing rates and companion diagnostic information.<\/li>\n<li>Real-world data augmentation.<\/li>\n<li>Patient journey and demographic characteristics.<\/li>\n<li>Real-world analysis of associated comorbidities and treatments.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-251404","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-oncology","biopharma-product-epidemiology","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251404","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251404\/revisions"}],"predecessor-version":[{"id":425385,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251404\/revisions\/425385"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251404"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}